- $67.55m
- $65.34m
- $0.03m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 31.46 | ||
| Price to Tang. Book | 31.46 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 2,412.6 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -139.05% | ||
| Return on Equity | -165.73% | ||
| Operating Margin | -10662.07% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 0.01 | 0.01 | 0.04 | 0.02 | 0.03 | n/a | n/a | 24.13% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Vivos Inc. is a radiation oncology medical device company. The Company has developed an Yttrium-90-based injectable Precision Radionuclide Therapy medical device to treat tumors in animals (IsoPet) and humans (RadioGel). Using the Company’s proprietary hydrogel technology, PRnT uses highly localized radiation to destroy cancerous tumors by placing a radioactive isotope directly inside the treatment area. The injection delivers therapeutic radiation from within the tumor without the entrance skin dose and associated side effects of treatment that characterize external-beam radiation therapy. This feature allows the safe delivery of higher doses needed for treating non-resectable and radiation-resistant cancers. University veterinary hospitals use the IsoPet Solutions division to demonstrate animal cancers’ safety and therapeutic effectiveness. RadioGel is a hydrogel liquid containing tiny yttrium-90 phosphate microparticles that may be administered directly into a tumor.
Directors
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- January 7th, 2000
- Public Since
- August 8th, 2001
- No. of Shareholders
- 232
- No. of Employees
- 10
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
Pink Sheets on Nasdaq- Shares in Issue
- 453,373,806
- Address
- 719 Jadwin Ave, RICHLAND, 99352-4217
- Web
- https://www.radiogel.com/
- Phone
- +1 5097364000
- Auditors
- Fruci & Associates II, PLLC
Upcoming Events for RDGL
Q2 2025 Vivos Inc Earnings Release
Q2 2025 Vivos Inc Earnings Release
Similar to RDGL
Aamaxan Transport
Pink Sheets on Nasdaq
ACCUSTEM SCIENCES
Pink Sheets on Nasdaq
Acutus Medical
Pink Sheets on Nasdaq
ADM Tronics Unlimited
Pink Sheets on Nasdaq
Advanced Biomedical Technologies
Pink Sheets on Nasdaq
FAQ
What is the Vivos share price?
As of Today at 24:02 UTC, shares in Vivos are trading at $0.15. This share price information is delayed by 15 minutes.
How has the Vivos share price performed this year?
Shares in Vivos last closed at $0.15 and the price had moved by -30.7% over the past 365 days. In terms of relative price strength the Vivos share price has underperformed the S&P500 Index by -35.74% over the past year.
What are the analyst and broker recommendations for Vivos?
There is no consensus recommendation for this security.
Find out moreWhat is the Vivos dividend yield?
Vivos does not currently pay a dividend.
Does Vivos pay a dividend?
Vivos does not currently pay a dividend.
When does Vivos next pay dividends?
Vivos does not currently pay a dividend.
How do I buy Vivos shares?
To buy shares in Vivos you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Vivos?
As of the previous close price of $0.15, shares in Vivos had a market capitalisation of $67.55m.
Where are Vivos shares listed?
Here are the trading details for Vivos:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: RDGL
What kind of share is Vivos?
Based on an overall assessment of its quality, value and momentum Vivos is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Vivos share price forecast for 2025?
We could not find analyst target price data for this security.
Find out moreWhat is the trend in the Vivos share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Vivos. Over the past six months, its share price has outperformed the S&P500 Index by +22.76%.
As of the last closing price of $0.15, shares in Vivos were trading +18.59% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Vivos PE Ratio?
The Vivos PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.15.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Vivos?
Vivos' management team is headed by:
- Carlton Cadwell - CHM
- Michael Korenko - PRE
- Michael Pollack - CFO